Pro-Life Advocacy Calls for HHS and FDA to Reassess Abortion Pill Safety Regulations

Pro-Life Advocacy Calls for HHS and FDA to Reassess Abortion Pill Safety Regulations

FIRST ON FOX: Live Action, a prominent pro-life organization, has urged the Trump administration to reevaluate the distribution protocols and reporting mechanisms associated with mifepristone, commonly known as “the abortion pill.”

The organization’s leadership has scheduled a press conference on Capitol Hill for Thursday to express their concerns about this abortion drug. Additionally, they will unveil a new investigative video from Live Action, which purportedly illustrates what they describe as the dangerous real-world distribution of mifepristone by Planned Parenthood and its affiliates. The organization accuses these entities of engaging in reckless distribution practices and asserts that the drug’s adverse effects are consistently underreported.

Concerns Voiced in Official Correspondence

In a formal letter addressed to Health and Human Services Secretary Robert F. Kennedy Jr. and U.S. Food and Drug Administration Commissioner Dr. Marty Makary, Live Action asserts its objective is to present evident regulatory violations and potential patient harm, calling for immediate actions from HHS and the FDA. This letter highlights the necessity of suspending mifepristone’s approval while also urging the prohibition of abortion pills dispensed via mail-order services and telehealth.

Furthermore, Live Action insists on reinstating comprehensive adverse-event reporting practices and demands a detailed public review of all scientific and clinical evidence utilized in the drug’s accessibility expansion.

The letter emphasizes, “Mifepristone has been legally available for over two decades through an expedited approval ensured by political influences. This process shielded the drug from transparency and has been expanded without sufficient regard for patient safety and compliance with legal standards,” as noted by Live Action Founder and President Lila Rose.

Current FDA Policies on Mifepristone

The FDA currently permits the prescription of mifepristone through telehealth appointments and allows its distribution by mail under a risk evaluation and mitigation strategy (REMS) program. The FDA warns against acquiring mifepristone outside of its REMS program, highlighting that doing so could bypass crucial health safeguards.

Adverse Effects Reported

Live Action’s correspondence brings attention to a 2025 report by the Ethics & Public Policy Center (EPPC), asserting that nearly 11 percent of women encountered adverse side effects within 45 days of using mifepristone. Among these side effects are severe complications such as sepsis, infections, and hemorrhaging.

The EPPC report indicates that the actual incidence of serious adverse events following mifepristone abortions stands at a staggering 22 times higher than the less than 0.5 percent figure cited in clinical trials associated with the drug’s labeling.

Investigative Findings on Planned Parenthood Practices

Additionally, Live Action has released a video allegedly documenting calls made to 27 Planned Parenthood facilities across the United States concerning the procurement of the abortion pill. This footage reportedly captures interactions in states like Alaska, Colorado, Kansas, and New York, among others.

In the initial part of the video, the caller inquires whether clinics require ultrasounds for prescribing the pill to establish the fetus’s gestational age. Many staff members at these facilities indicated that patients could obtain the pill without undergoing an ultrasound through a telehealth consultation.

Follow-Up Recommendations and Rh Testing

In a subsequent section of the video, the caller was informed that Planned Parenthood did not conduct testing for Rhesus (Rh) incompatibility. Rh factor is a blood protein that can lead to complications in subsequent pregnancies. A 2020 document from Planned Parenthood of Greater New York acknowledged the potential for individuals to develop Rh antibodies, affecting their future pregnancies, though it stated current research has not confirmed this risk.

Live Action’s footage also indicated that personnel answering phones at varied Planned Parenthood locations reassured callers that extensive medical histories or in-person follow-ups were unnecessary.

Although the qualifications of the staff members who interacted with the caller remain unclear, one participant suggested she consult a medical professional for more precise insights regarding her inquiries.

Issues of Confidentiality and Patient Safety

In conversations with clinics across multiple locales, the respondents purportedly claimed that callers could have prescribed pills sent to a different address. When asked about the urgency of taking the pills, most said immediate action was not necessary, with some even suggesting the caller could delay the decision. Nevertheless, a representative from one clinic specified that the pill needed to be taken within 12 weeks for effectiveness.

March for Life and Planned Parenthood’s Response

The release of Live Action’s letter and video comes ahead of the annual March for Life, scheduled for January 23. Notable speakers at the event will include Vice President JD Vance, who announced his family is expecting their fourth child, along with House Speaker Mike Johnson and Rep. Chris Smith.

In response to these accusations, Planned Parenthood asserted the adherence of their health centers offering medication abortion to all pertinent laws and regulations while emphasizing their commitment to patient care based on the latest credible research.

Planned Parenthood Vice President of Care and Access Danika Severino affirmed that mifepristone is a safe and legal option utilized by more than 7.5 million individuals for abortion and miscarriage management since its FDA approval 25 years ago. Severino cautioned that the ongoing spread of misinformation by anti-abortion activists undermines the factual representation of the drug’s safety and efficacy.

Fox News Digital has attempted to obtain additional comments from HHS and the FDA regarding this situation.

A Continuing Debate on Abortion Regulations

The ongoing discussion surrounding mifepristone and the practices of abortion providers like Planned Parenthood continues to intensify as various stakeholders advocate for patient safety and transparency in reproductive healthcare. Live Action’s efforts highlight the need for rigorous oversight and accountability in pharmaceutical distribution practices, drawing attention to the critical discourse over abortion access and the responsibilities of healthcare providers.